The Proteomics Market was valued at USD 27.78 Billion in 2024, and is projected to reach USD 58.16 Billion by 2030, rising at a CAGR of 12.90%. The major factors driving theindustry growth are a rise in the demand for personalized medicine, an expansion of the pipeline of diagnostics utilizing proteomics mass spectrometry as well as biochip platforms, and discoveries based on genomics. Moreover, owing to the importance of proteomics in drug development, numerous pharmaceutical companies have established their own proteomic divisions, which are fueling the expansion of the global industry. For instance, in September 2021, Biognosys, announced the collaboration with Evotec, to promote the use of next-generation proteomics in clinical research and drug discovery.
The COVID-19 outbreak is expected to have a significant impact on the industry, as researchers across the world are concentrating on decoding 3D structures of SARS-CoV-2 proteins. To create effective medications and biological products against COVID-19, scientists are also attempting to examine the identification techniques, structures, characterization, and interactions of these proteins. The protein structure of virus proteins and their specific locations must be understood to find a novel, efficient target treatment medication for a virus. Therefore, it will increase the demand for drug development for COVID-19 and propel industry growth. The growing need for customized medications increased R&D spending, and technological developments related to proteomics components are also driving the market.
In addition, attractive market expansion potential for proteomics is anticipated to come from improvements in mass spectrometry-based proteomics and lucrative opportunities related to biomarker identification. Thereby, propelling the market growth.The introduction of new and improved proteomics techniques by major industry participants is projected to further accelerate the growth of the industry. For instance, to provide quick data acquisition for shotgun proteomics, Bruker Corp. introduced the timsTOF Pro system for Parallel Accumulation and Serial Fragmentation (PASEF) mass spectrometry in September 2017. This system uses proprietary Trapped Ion Mobility Spectrometry (TIMS) technology.Furthermore, proteomic research advancements have accelerated the detection of protein biomarkers, protein biochips & pharmacoproteomics, and proteomics-based molecular diagnostics, which have all made significant contributions to the development of personalized medicine.
This product will be delivered within 2 business days.
The COVID-19 outbreak is expected to have a significant impact on the industry, as researchers across the world are concentrating on decoding 3D structures of SARS-CoV-2 proteins. To create effective medications and biological products against COVID-19, scientists are also attempting to examine the identification techniques, structures, characterization, and interactions of these proteins. The protein structure of virus proteins and their specific locations must be understood to find a novel, efficient target treatment medication for a virus. Therefore, it will increase the demand for drug development for COVID-19 and propel industry growth. The growing need for customized medications increased R&D spending, and technological developments related to proteomics components are also driving the market.
In addition, attractive market expansion potential for proteomics is anticipated to come from improvements in mass spectrometry-based proteomics and lucrative opportunities related to biomarker identification. Thereby, propelling the market growth.The introduction of new and improved proteomics techniques by major industry participants is projected to further accelerate the growth of the industry. For instance, to provide quick data acquisition for shotgun proteomics, Bruker Corp. introduced the timsTOF Pro system for Parallel Accumulation and Serial Fragmentation (PASEF) mass spectrometry in September 2017. This system uses proprietary Trapped Ion Mobility Spectrometry (TIMS) technology.Furthermore, proteomic research advancements have accelerated the detection of protein biomarkers, protein biochips & pharmacoproteomics, and proteomics-based molecular diagnostics, which have all made significant contributions to the development of personalized medicine.
Proteomics Market Report Highlights
- Chronic diseases, such as cardiovascular conditions, diabetes, and cancer, account for a substantial portion of global morbidity and mortality.
- The proteomics industry is experiencing a significant degree of innovation driven by technological advancements in mass spectrometry and next-generation sequencing technology.
- The reagents & consumables segment accounted for the largest revenue share of 72.53% in 2024. Kits designed for mass spectrometry enable researchers to identify proteins within complex biological samples accurately
- The spectrometry segment captured the largest revenue share of 31.88% in 2024. It is also expected to expand further at the highest during the forecast period
- The drug discovery segment dominated the proteomics market with the largest revenue share of 52.73% in 2024. This large share can be attributed to the development of structure-based drug design, a greater emphasis on creating personalized drugs, and increased investments in these areas.
- North America Proteomics market dominated the global market and accounted for 45.75% revenue share in 2024, owing to the advancements in technology and growing demand for advanced disease diagnostics
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Proteomics Market Variables, Trends & Scope
Chapter 4. Proteomics Market: Product & Service Estimates & Trend Analysis
Chapter 5. Proteomics Market: Application Estimates & Trend Analysis
Chapter 6. Proteomics Market: Technology Estimates & Trend Analysis
Chapter 7. Proteomics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Proteomics market report include:- Illumina, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Bruker Corporation
- F. Hoffmann-La Roche Ltd.
- Waters Corporation
- Merck KGaA
- Danaher
- Standard BioTools Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 27.78 Billion |
| Forecasted Market Value ( USD | $ 58.16 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
